Amrita Krishnan, M.D.

(877) 460-4673
Amrita Krishnan, M.D.
Hematologist
Clinical Expertise
Multiple Myeloma
Hematopoietic Cell Transplantation
Research Area
Multiple Myeloma
Myeloma
Hematology and Hematopoietic Cell Transplantation
Other Languages Spoken
French
Appointments
Executive Medical Director, Hematology, City of Hope Orange County
Director, Judy and Bernard Briskin Multiple Myeloma Center
Professor, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Bone Marrow and Stem Cell Transplantation
Myeloma and Multiple Myeloma
Hematology & Hematopoietic Cell Transplantation
Equally driven as a clinician and researcher, Amrita Krishnan, M.D., was instrumental in bringing successful transplant therapy to HIV patients with lymphoma, when many believed such patients were too weak to tolerate the procedure.
 
“We have patients who had been told to get their affairs in order,” she says. “Years later, they are still here.”
 
Dr. Krishnan now directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, seeking to make gains in one of the most rapidly changing areas in cancer research.
 
A key member of the City of Hope team since 1996, Dr. Krishnan trained at The University of Rochester, Beth Israel Hospital, Fred Hutchinson Research Cancer Center and Dana Farber Cancer Institute.  Serves as a steering committee member on the Multiple Myeloma Research Foundation and the North American representative to the International Myeloma Society, former chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee and is the Co-Chair of several of the largest myeloma transplant trials in the U.S.
 
Her research interests are in development of new drugs for relapsed myeloma and unserstanding mechanisms of disease resistance.
Location
Education & Experience
Degrees

  • 1990, Albany Medical College, Albany, NY, M.D., Medicine

  • 1988, Union College, Schenectady, NY, B.S., Biology/Modern Languages

Fellowship

  • 1996 - 1997, Clinical Fellow, Bone Marrow Transplantation City of Hope

  • 1993 - 1996, Clinical Fellow, Hematology-oncology Beth Israel Hospital, Harvard University Boston MA

  • 1993 - 1996, Clinical Fellow Clinical Fellow in Medicine, Harvard Medical School Boston MA

  • 1995 - 1996, Research Fellow Division of Hematologic Malignancies, Principal Investigator, J. Ritz Dana Farber Cancer Institute Harvard University, Boston MA

  • 1995, Clinical Fellow, Bone Marrow Transplantation Fred Hutchinson Cancer Research Center, University of Washington Seattle WA

  • 1995, Clinical Fellow, Bone Marrow Transplantation, Solid Tumor and Lymphoma Autologous Marrow Program Dana Farber Cancer Institute and Beth Israel Hospital, Boston, MA

Residency

  • 1991 - 1993, Strong Memorial Hospital University of Rochester, Rochester, NY

Professional Experience

  • 2022-present, Executive Medical Director, Hematology, City of Hope Orange County

  • 2021-present, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2015-present, Director, Judy and Bernard Briskin Center for Myeloma, City of Hope, Duarte, CA

  • 2004-2018, Associate Director, Medical Education and Training, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope

  • 1997-present, Staff Physician, Department of Hematology and Hematopoietic Cell Transplantation City of Hope

Publications

  • A Chari, M.D., MC. Minnema, M.D., JG. Berdeja, M.D., A Oriol, M.D., Ph.D., N van de Donk, M.D., Ph.D., P Rodríguez-Otero, M.D., Ph.D., E Askari, M.D., M Mateos, M.D., Ph.D., LJ. Costa, M.D., Ph.D., JCaers, M.D., Ph.D., R Verona, Ph.D., S Girgis, Ph.D., S Yang, Ph.D., RB. Goldsmith, Ph.D., X Yao, Ph.D., K Pillarisetti, M.Sc., BW. Hilder, Ph.D., J Russell, M.D., Ph.D., JD. Goldberg, M.D., and A Krishnan, M.D. “Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.” N Engl J Med 2022; 387:2232-2244, DOI: 10.1056/NEJMoa2204591. December 15, 2022

  • P. Moreau, A.L. Garfall, N.W.C.J. van de Donk, H. Nahi, J.F. San-Miguel, A. Oriol, A.K. Nooka, T. Martin, L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M.-V. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez-López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S.X.W. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Van Rampelbergh, A. Banerjee, J.D. Goldberg, R. Kobos, A. Krishnan, and S.Z. Usmani. “Teclistamab in Relapsed or Refractory Multiple Myeloma.” N Engl J Med 2022;387:495-505. DOI: 10.1056/NEJMoa2203478. June 5, 2022

  • Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.  J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17. PMID: 30653422

  • A Krishnan, P Sonneveld. Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma? Lancet Haematol. 2020 Jun;7(6):e445-e446. doi: 10.1016/S2352-3026(20)30149-6.PMID: 32470436 

  • Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2020 Aug 11. Online ahead of print. PMID: 32778736
  • Krishnan A, Adhikarla V, Poku EK et al. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020 Oct 27;4(20):5194-5202. doi: 10.1182/bloodadvances.2020002603.PMID: 33095874.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
Ratings
4.9
Know important info medical history
4.8
Show respect for what you say
4.8
Spend enough time with you
4.8
Rate provider 0-10
4.8
Recommend this provider office
4.8
Provider explain in way you understand
4.8
Provider listen carefully to you
Reviews
07/15/23
I have sent everyone I know with any cancer to COH. Those who chose wisely and joined the club, have all been very grateful. - Verified patient
07/15/23
Dr Krishnan continues to amaze me in her brilliance to treat all of us who have multiple myeloma so specific to each of us as an individual as we are all so different. [...] I feel the blood tests, and all testing is fashion forward to get ahead of this non curable disease. When numbers change Dr K is ON IT!! This woman is saving her patients one at a time. On [...] when I saw her, and we reviewed my blood work, went over my 6 th month tests coming up in [...], she said, "I have nothing to say to you!" NOW THAT IS MUSIC TO A PATIENT'S EARS! I love having Dr K at the helm!! Blessed to have City of Hope as my army!! - Verified patient
06/30/23
The care and treatment at City of Hope has been terrific. - Verified patient
06/20/23
Dr Krishnan was very thorough and answered all questions and concerns. She made me feel very confident and comfortable in her care! - Verified patient
04/28/23
Dr Krishnan is the best - Verified patient